HCWB · HCW Biologics Inc.
$2.57
-0.08 (-3.02%)
At close · Jul 28
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company believes that substantial doubt exists regarding its ability to continue as a going concern for at least 12 months from the date of issuance of the Company's condensed financial statements and that the substantial doubt that existed in its going concern analysis was not alleviated.”View the 10-Q filed May 14, 2026
Market Cap
$17.41M
Shares
6.73M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$54.23K
-97.9%
FY2025
Net Income
-$7.96M
+73.5%
FY2025
Gross Margin
20%
-17.4pp
FY2025
Operating Margin
-24270.74%
-23123.1pp
FY2025
Diluted EPS
-$63.78
+65.7%
FY2025
Operating Cash Flow
-$13.39M
+5.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $6.55M | $54.23K | $2.57M | $2.84M | $6.72M | $0 | $4.1M | |
| $50.41K | $43.39K | $1.61M | $2.28M | $4.14M | $0 | — | |
| $6.54M | $10.85K | $959.4K | $560.36K | $2.59M | $0 | — | |
| — | 20% | 37.38% | 19.72% | 38.48% | — | — | |
| $5.22M | $5.44M | $6.39M | $7.68M | $9.34M | $8.17M | $7.26M | |
| $7.31M | $7.7M | $6.82M | $6.78M | $8.33M | $5.19M | $2.67M | |
| — | $1.04M | $1.18M | $1.14M | $717.85K | $543.6K | $572.87K | |
| $14.5M | $13.17M | $30.42M | $26.28M | $17.67M | $13.37M | $9.92M | |
| -$7.96M | -$13.16M | -$29.46M | -$25.72M | -$15.08M | -$13.37M | -$5.82M | |
| — | -24270.74% | -1147.6% | -904.96% | -224.32% | — | -142.07% | |
| — | -$12.12M | -$28.27M | -$24.58M | -$14.36M | -$12.82M | -$5.25M | |
| $698.5K | $845.05K | $654.28K | $283.04K | $126.66K | $0 | — | |
| — | $0 | -$1.3M | — | — | — | — | |
| — | -$273.42K | $0 | — | — | — | — | |
| — | -$7.96M | -$30.02M | -$24.99M | -$14.9M | -$12.86M | -$5.8M | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$2.29M | -$7.96M | -$30.02M | -$24.99M | -$14.9M | -$12.86M | -$5.8M | |
| — | -14677.14% | -1169.7% | -879.52% | -221.67% | — | -141.53% | |
| -$18.12M | -$22.3M | -$30.02M | — | — | -$12.86M | -$7.07M | |
| USD/shares | — | -$63.78 | -$185.76 | -$168.00 | -$100.80 | -$165.60 | — |
| USD/shares | — | -$63.78 | -$185.76 | -$168.00 | -$100.80 | -$165.60 | — |
| shares | — | 349.62K | 161.64K | 149.71K | 149.26K | 78.21K | 19.75K |
| shares | — | 349.62K | 161.64K | 149.71K | 149.26K | 78.21K | 19.75K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 18.85×
EV/EBIT
—
P/E (TTM)
—
Peer median 0.17×
Peer medians compare against the 233 similar-size Biotechnology companies (of 522 listed).